The new chief executive officer of Pharming Group NV has outlined a strategy for the Dutch company that involves building up a broadly based portfolio of products in the fields of biotechnology, biomaterials and bionutritionals. The purpose is to reduce the group’s dependence on any one product. Pharming’s lead product for acute attacks of hereditary angioedema (HAE), Rhucin, encountered regulatory obstacles in 2008.
